医学
阿司匹林
队列
动脉粥样硬化性心血管疾病
弗雷明翰风险评分
比例危险模型
前瞻性队列研究
队列研究
内科学
随机对照试验
人口学
疾病
社会学
作者
Michelle A. Fravel,Michael E. Ernst,Robyn L. Woods,Suzanne G. Orchard,Shiva Ganjali,James B. Wetmore,Christopher M. Reid,Joanne Ryan,Kevan R. Polkinghorne,Rory Wolfe,Mark Nelson,Sophia Zoungas,Zhen Zhou
标识
DOI:10.1161/circoutcomes.124.011719
摘要
BACKGROUND: The ability of the American Heart Association Predicting Risk of Cardiovascular Disease Events (PREVENT) calculator to accurately assign 10-year atherosclerotic cardiovascular disease (ASCVD) risk in older individuals, including those aged ≥80 years, is unknown. This study compares PREVENT with the 2013 Pooled Cohort Equation (PCE) calculator for predicting 10-year ASCVD risk in a large cohort of older adults. METHODS: This was a prospective cohort study of adults without CVD from Australia and the United States aged ≥70 years (≥65 years, if US minorities). They were enrolled from 2010 to 2014 in the ASPREE trial (Aspirin in Reducing Events in the Elderly), a 5-year randomized trial of low-dose aspirin in community-dwelling older adults with posttrial observational follow-up extending to 2022. ASCVD events were adjudicated by expert panels. The discriminative ability of the 2 risk calculators was assessed by Harell C statistic following Cox regression in the 65- to 79-year age group and >80-year age group, separately. For calibration, predicted event numbers were calculated using PREVENT and PCE, scaled for the actual length of follow-up, and compared with the number of observed events in-trial and during extended follow-up. RESULTS: Among the 15 510 participants aged 65 to 79 years (median age, 73.2 years; 56.1% women), 1084 ASCVD events occurred (median follow-up, 8.3 years); PCE predicted 3102 events while PREVENT predicted 1290 events. For the 2787 participants ≥80 years (median age, 82.6 years; 59.2% women), 355 ASCVD events occurred (median follow-up, 7.4 years); PCE predicted 1067 events while PREVENT predicted 350 events. PREVENT showed superior discriminative performance compared with PCE (PREVENT versus PCE, C statistic, 0.793 versus 0.740; P <0.001 in participants aged 65 –79 years; 0.854 versus 0.799; P <0.001 in those aged ≥80 years). CONCLUSIONS: The PREVENT risk calculator is superior to the PCE calculator in predicting ASCVD events in older adults from the United States and Australia, including those aged ≥80 years. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01038583. URL: https://www.isrctn.com ; Unique identifier: ISRCTN83772183.
科研通智能强力驱动
Strongly Powered by AbleSci AI